Difficulties in management of patients with systemic lupus erythematosus and antiphospholipid syndrome in combination with melanoma and infiltrative tuberculosis (clinical observations)
https://doi.org/10.14412/1996-7012-2021-4-87-93
Abstract
We present two clinical cases: the first patient had combination of antiphospholipid syndrome (APS) and melanoma, and the second – systemic lupus erythematosus (SLE) and APS, melanoma, infiltrative tuberculosis and Herpes zoster. Managing patients with SLE combined with APS is really challenging. Infections and malignant neoplasms, along with kidney damage and cardiovascular diseases, are a significant cause of death in this cohort of patients. The role of antibodies to phospholipids in the onset of malignancy is still under discussion. The combination of rheumatic diseases with oncological or infectious pathology complicates therapy, limiting the use of drugs, recommended by clinical guidelines.
Keywords
antiphospholipid syndrome,
systemic lupus erythematosus,
melanoma,
pulmonary tuberculosis,
clinical observations
Supporting agencies: The investigation has been conducted within scientific topic «Development of methods for personalized therapy of rheumatic diseases with comorbid pathology» (№АААА-А19-119021190151-3, 0514-2019-0020).
About the Authors
A. A. Shumilova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Anastasia Aleksandrovna Shumilova
Kashirskoye shosse, 34A, Moscow 115522
T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Department of Rheumatology
Kashirskoye shosse, 34A, Moscow 115522
2/1, Barrikadnaya St., Build. 1, Moscow 125993
F. A. Cheldieva
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Department of Rheumatology
Kashirskoye shosse, 34A, Moscow 115522
2/1, Barrikadnaya St., Build. 1, Moscow 125993
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Department of Rheumatology
Kashirskoye shosse, 34A, Moscow 115522
2/1, Barrikadnaya St., Build. 1, Moscow 125993
References
1. Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p..
2. D'Cruz DP, Mellor-Pita S, Joven B, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol. 2004 Feb;31(2):280-5.
3. Nasonov EL. Antifosfolipidnyi sindrom. Monografiya [Antiphospholipid syndrome. Monograph]. Moscow: Littera; 2004. 36 p.
4. Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (lecture). Nauchno-prakticheskaya revmatologiya. 2014;52(1):56-71. (In Russ.).
5. Ocampo-Piraquive V, Nieto-Aristizabal I, Canas CA, Tobon GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. 2018 Dec;14(12):1043-53. doi: 10.1080/1744666X.2018.1538789.
6. Rodriguez-Pinto I, Moitinho M, Santacreu I, et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016 Dec;15(12): 1120-4. doi: 10.1016/j.autrev.2016.09.010. Epub 2016 Sep 15.
7. Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992 Apr;51(4):437-9. doi: 10.1136/ard.51.4.437.
8. Islam MA. Antiphospholipid antibodies and antiphospholipid syndrome in cancer: Uninvited guests in troubled times. Semin Cancer Biol. 2020 Aug;64:108-13. doi: 10.1016/j.semcancer.2019.07.019. Epub 2019 Jul 24.
9. Mendoza-Pinto C, Garcia-Carrasco M, Cervera R. Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant). Curr Rheumatol Rep. 2018 Aug 20;20(10):62. doi: 10.1007/s11926-018-0773-x.
10. Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. Nov-Dec 2014;28(6):1005-11.
11. Rigel DS. Epidemiology of melanoma. Semin Cutan Med Surg. 2010 Dec;29(4): 204-9. doi: 10.1016/j.sder.2010.10.005.
12. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005 Jan;41(1):45-60. doi: 10.1016/j.ejca.2004.10.016.
13. Cao L, Tong H, Xu G, et al. Systemic lupus erythematous and malignancy risk: a meta-analysis. PLoS One. 2015 Apr 17;10(4): e0122964. doi: 10.1371/journal.pone.0122964. eCollection 2015.
14. Singh AG, Crowson CS, Singh S, et al. Cancer risk in cutaneous lupus erythematosus: a population-based cohort study. Rheumatology (Oxford). 2016 Nov;55(11):2009-13. doi: 10.1093/rheumatology/kew291. Epub 2016 Aug 12.
15. Chow MT, Möller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012 Feb;22(1): 23-32. doi: 10.1016/j.semcancer.2011.12.004. Epub 2011 Dec 24.
16. Yadav S, Singh S, Harmsen WS, et al. Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota. Mayo Clin Proc. 2015 Jun;90(6):738-46. doi: 10.1016/j.mayocp.2015.03.024. Epub 2015 May 9.
17. Trousseau A. Phlegmasia alba dolens Clinique Medical de L'HotelDieu de Paris. Vol. 3. London: The New Sydenham Society; 1865. 94 p.
18. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003 Jun 17;107(23 Suppl 1): I17-21. doi: 10.1161/01.CIR.0000078466.72504.AC.
19. Wuepper KD, Tuffanelli DL. False-positive reaction to VRDL test with prozone phenomena. Association with lymphosarcoma. JAMA. 1966 Mar 7;195(10):868-9. doi: 10.1001/jama.1966.03100100120044.
20. Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood. 1976 Oct;48(4): 499-509.
21. Falcon CR, Hoffer AM, Carreras LO. Antiphosphatidylinositol antibodies as markers of the antiphospholipid syndrome. Thromb Haemost. 1990 Apr 12;63(2):321-2.
22. Stern JJ, Ng RH, Triplett DA, McIntyre JA. Incidence of antiphospholipid antibodies in patients with monoclonal gammopathy of undetermined significance. Am J Clin Pathol. 1994 Apr;101(4):471-4. doi: 10.1093/ajcp/101.4.471.
23. Zuckerman E, Toubi E, Golan TD, et al. Increased thromboembolic incidence in anticardiolipin-positive patients with malignancy. Br J Cancer. 1995 Aug; 72(2): 447-51. doi: 10.1038/bjc.1995.353.
24. Gomez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006 Apr;35(5):322-32. doi: 10.1016/j.semarthrit.2005.07.003.
25. Choi MY, Flood K, Bernatsky S, Ramsey-Goldman R, Clarke AE. A review on SLE and malignancy. Best Pract Res Clin Rheumatol. 2017 Jun;31(3):373-396. doi: 10.1016/j.berh.2017.09.013.
26. Song L, Wang Y, Zhang J, et al. The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Arthritis Res Ther. 2018 Dec 6;20(1):270. doi: 10.1186/s13075-018-1760-3.
27. Jacobs JVG, Bijlsma JVG. Glucocorticoid therapy. In Firestein GS, Budd RC, Gabriel SE, editors. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia: Elsevier; 2017. P. 932-57.
28. Yablonskii PK, editor. Ftiziatriya. Natsional'nye klinicheskie rekomendatsii [Phthisiology. National clinical guidelines]. Moscow: GEOTAR-Media; 2016. 240 p.
29. Ghosh K, Patwardhan M, Pradhan V. Mycobacterium tuberculosis infection precipitates SLE in patients from endemic areas. Rheumatol Int. 2009 Jul;29(9):1047-50. doi: 10.1007/s00296-009-0903-x. Epub 2009 Apr 10.
30. Hernandez-Cruz B, Sifuentes-Osornio J, Ponce-de-Leon Rosales S, et al. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol. 1999 May-Jun;17(3): 289-96.
31. Park DW, Chung SJ, Yeo Y, et al. Therapeutic issues with, and long-term outcomes of, pulmonary mycobacterial tuberculosis treatment in patients with autoimmune rheumatic diseases. J Thorac Dis. 2019 Nov; 11(11):4573-82. doi: 10.21037/jtd.2019.10.74.
32. Gatto M, Saccon F, Zen M, et al. Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. J Autoimmun. 2016 Nov;74:94-105. doi: 10.1016/j.jaut.2016.06.014. Epub 2016 Jun 30.
33. Stohl W, Schwarting A, Okada M, et al. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017 May;69(5):1016-27. doi: 10.1002/art.40049. Epub 2017 Apr 7.
34. Diaz-Lagares C, Perez-Alvarez R, Garcia-Hernandez FJ, et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther. 2011 Jul 11;13(4):R112. doi: 10.1186/ar3397.
Review
For citations:
Shumilova AA, Reshetnyak TM, Cheldieva FA, Lila AM. Difficulties in management of patients with systemic lupus erythematosus and antiphospholipid syndrome in combination with melanoma and infiltrative tuberculosis (clinical observations). Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(4):87-93. (In Russ.) https://doi.org/10.14412/1996-7012-2021-4-87-93
Views:
531
Email this article 